ENDRA Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

ENDRA Life Sciences şirketinin toplam hissedar öz sermayesi $6.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $8.4M ve $1.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$4.75m
Eşitlik	US$6.60m
Toplam yükümlülükler	US$1.77m
Toplam varlıklar	US$8.38m

Son finansal sağlık güncellemeleri

Recent updates

ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks

Sep 29

We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully

Jul 19

ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer

Jun 15

ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology

Jan 13

ENDRA Life Sciences renews GE Healthcare collaboration agreement

Dec 21

Endra Life prices $5M-share offering

Dec 16

Endra Life Sciences EPS beats by $0.02

Nov 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NDRA 'nin kısa vadeli varlıkları ( $5.0M ) kısa vadeli yükümlülüklerini ( $814.0K ) aşıyor.

Uzun Vadeli Yükümlülükler: NDRA şirketinin kısa vadeli varlıkları ( $5.0M ) uzun vadeli yükümlülüklerini ( $960.4K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NDRA borçsuzdur.

Borcun Azaltılması: NDRA şirketinin 5 yıl önce borç/öz sermaye oranı 46.5% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NDRA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: NDRA un, serbest nakit akışı her yıl % 5.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

ENDRA Life Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

ENDRA Life Sciences Inc. announced delayed 10-Q filing

ENDRA Life Sciences Inc. announced delayed 10-Q filing

Nasdaq Hearings Panel Grants ENDRA Life Sciences an Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

ENDRA Life Sciences Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Recent updates

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

ENDRA Life Sciences Inc. announced delayed 10-Q filing

ENDRA Life Sciences Inc. announced delayed 10-Q filing

Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting 2024

Nasdaq Hearings Panel Grants ENDRA Life Sciences an Extension to Regain Compliance with Nasdaq Continued Listing Requirements

ENDRA Life Sciences Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

New major risk - Financial position

ENDRA Life Sciences Inc. Announces Chief Executive Officer Changes

ENDRA Life Sciences Inc. to Report Q2, 2024 Results on Aug 14, 2024

ENDRA Life Sciences Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

ENDRA Life Sciences Inc., Annual General Meeting, Aug 06, 2024

Consensus revenue estimates decrease by 50%, EPS upgraded

New major risk - Shareholder dilution

Endra Life Sciences Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024

ENDRA Life Sciences Inc. Provides Earnings Guidance for the Quarter Ended March 31, 2024

ENDRA Life Sciences Inc. to Report Q1, 2024 Results on May 14, 2024

Endra Life Sciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Marketplace Rule 5550(a)(2)

New major risk - Revenue and earnings growth

ENDRA Life Sciences Inc. has filed a Follow-on Equity Offering in the amount of $6.2 million.

New major risk - Market cap size

ENDRA Life Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

ENDRA Life Sciences Inc. Welcomes the Adoption of the ICD-10 K76.0 Code for the Diagnosis of Non-Alcoholic Fatty Liver Disease

ENDRA Life Sciences Inc. has filed a Follow-on Equity Offering in the amount of $6.2 million.

New major risk - Market cap size

New major risk - Revenue and earnings growth

ENDRA Life Sciences Inc. to Report Q3, 2023 Results on Nov 14, 2023

ENDRA Life Sciences Submits De Novo Request for its TAEUS System Liver Fat Application to the U.S. FDA

ENDRA Life Sciences Inc. to Report First Half, 2023 Results on Aug 14, 2023

ENDRA Life Sciences Inc., Annual General Meeting, Aug 09, 2023

New major risk - Market cap size

Consensus revenue estimates decrease by 90%, EPS upgraded

ENDRA Life Sciences Inc., Annual General Meeting, Jul 06, 2023

ENDRA Life Sciences Inc. to Report Q1, 2023 Results on May 15, 2023

Insufficient new directors

Consensus revenue estimates increase by 57%, EPS downgraded

ENDRA Life Sciences Inc. Announces Resignation of Renaud Maloberti as Chief Commercial Officer, Effective January 13, 2023

Consensus forecasts updated

ENDRA Life Sciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

ENDRA Life Sciences Inc. Plans to Submit De Novo Request to U.S. FDA for Its TAEUS System

ENDRA to submit FDA De Novo request for liver disease monitoring system in coming weeks

Consensus revenue estimates fall by 39%

Price target decreased to US$4.75

ENDRA Life Sciences receives European patent for TAEUS system

Endra Life Sciences Q2 2022 Earnings Preview

We're A Little Worried About ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

ENDRA Life Sciences Inc. to Report Q2, 2022 Results on Aug 15, 2022

Consensus revenue estimates fall by 21%

Consensus forecasts updated

ENDRA Life Sciences Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$5.25

Consensus revenue estimates fall by 79%

Price target decreased to US$5.63

ENDRA Life Sciences Inc. Provides Update on U.S. Regulatory Strategy for its TAEUS® System

We're Keeping An Eye On ENDRA Life Sciences' (NASDAQ:NDRA) Cash Burn Rate

Price target increased to US$6.50

Independent Director recently sold US$92k worth of stock

Price target increased to US$6.25

We Think ENDRA Life Sciences (NASDAQ:NDRA) Needs To Drive Business Growth Carefully

ENDRA Life Sciences names Irina Pestrikova Principal Financial Officer

Consensus forecasts updated

ENDRA Life Sciences Inc. to Report Q4, 2020 Results on Mar 25, 2021

ENDRA Life Sciences granted 13th U.S. Patent for its TAEUS platform technology

New 90-day high: US$0.92

ENDRA Life Sciences renews GE Healthcare collaboration agreement

ENDRA Life Sciences Inc. has completed a Follow-on Equity Offering in the amount of $5.0001 million.

Endra Life prices $5M-share offering

New 90-day high: US$0.90

ENDRA Life Sciences Announces New Clinical Study Partnership with the Centre Hospitalier Universitaire d'Angers, France

New 90-day high: US$0.85